Clinical Significance of National Institutes of Health-Chronic Prostatitis Symptom Index Pain Score in Patients with Benign Prostatic Hyperplasia

Purpose: Many benign prostatic hyperplasia (BPH) patients were accompanied by pelvic pain apart from urinary symptoms. Therefore, we evaluate the treatment outcomes of alpha-blockers via a change of international prostate symptom score (IPSS) according to pain score of the National Institutes of Hea...

Full description

Saved in:
Bibliographic Details
Published inUrogenital tract infection Vol. 10; no. 2; pp. 102 - 107
Main Authors Lee, Chang Min, Song, Jae Mann, Kim, Kwang Jin, Kang, Tae Wook, Ryang, Seung Hoon, Chae, Yun Byung, Chung, Hyun Chul, Jung, Jae Hung
Format Journal Article
LanguageEnglish
Published 대한요로생식기감염학회 01.10.2015
Subjects
Online AccessGet full text
ISSN2465-8243
2465-8510
2465-8510
DOI10.14777/uti.2015.10.2.102

Cover

More Information
Summary:Purpose: Many benign prostatic hyperplasia (BPH) patients were accompanied by pelvic pain apart from urinary symptoms. Therefore, we evaluate the treatment outcomes of alpha-blockers via a change of international prostate symptom score (IPSS) according to pain score of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI).Materials and Methods: A total of 356 male patients with BPH from March 2011 to May 2014 were analyzed retrospectively. Prostate specific antigen, prostate volume, IPSS, NIH-CPSI, international index of erectile function (IIEF-5), and uroflowmetry were collected. Patients were categorized according to 2 groups based on the presence and severity of pain and baseline characteristics and treatment outcomes were analyzed.Results: Two hundred twenty-nine patients (64.3%) reported pain/discomfort on NIH-CPSI. Mean IPSS, mean voiding symptoms, mean storage symptoms on IPSS, and mean IIEF-5 showed a significant difference in groups 1A and 1B. Logistic regression analysis showed that NIH-CPSI pain score was a significant predictive factor for severe IPSS (odds ratio, 2.830; 95% confidence interval, 1.307-6.129). After treatment for 3 months, improvement of IPSS, voiding symptoms, storage symptoms, and quality of life was observed in all groups (p=0.001, p<0.001, p=0.026, p<0.001, p<0.001, p<0.001, p<0.001, p<0.001). Group 2B (pain score>5) showed greater improvement of symptoms and statistically significant difference compared with group 2A (pain score ≤5) (p=0.029, p=0.026).Conclusions: We suggest that the presence and severity of pain score are helpful for therapeutic efficacy in patients with BPH. KCI Citation Count: 0
Bibliography:G704-SER000001539.2015.10.2.007
ISSN:2465-8243
2465-8510
2465-8510
DOI:10.14777/uti.2015.10.2.102